Clinical trial SOLSTICE
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Shire |
| EudraCT Identifier | 2015-004725-13 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02931539 |
| Inclusion criteria | HSCT, refractory or resistant CMV reactivation |
| Last update |